Mike Benson

Cannabis industry ETFs are designed for those who can’t hold many stocks but are interested in diversifying within the cannabis sector.

In this article, we’ll discuss the performances of a few stocks from the cannabis industry (SEED) for the week that ended on November 30.

The cannabis industry (HMMJ) reported a fall in the last week of November, which ended on November 30.

iAnthus Capital Holdings (ITHUF) is a leading company in the cannabis industry (SEED).

iAnthus Capital Holdings announced in October that it had entered into an acquisition agreement with MPX Bioceutical for the acquisition of MPX’s US assets.

Curaleaf Holdings (LDVTF) has entered into a few agreements for the expansion of its presence, and it’s also achieved a few milestones this year.

For the third quarter of 2018, Wall Street analysts estimate Curaleaf Holdings to report revenues of ~28.1 million Canadian dollars.

ETFs investing in cannabis stocks The chart below compares ETFs’ returns in the last week. Horizons Marijuana Life Sciences Index ETF (HMMJ) This ETF focuses on North American publicly listed life sciences companies with significant business in the cannabis industry. The fund has operated since April 2017, and its market capitalization is 785.9 million Canadian […]

MedMen stock has fallen ~29.6% in November. The stock fell 26.3% in the last five trading sessions to close at $3.52 on November 20.

Trulieve reported revenues of $28.3 million during the third quarter of 2018 as compared to Wall Street analyst estimates of $26.6 million during the quarter.

Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET.

On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.

MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.

MedMen (MMNFF) has three cultivation and production factories in Florida, Nevada, and New York.

MedMen’s (MMNFF) reported revenues are generated from direct sales through its retail stores. The company has reported no material revenues from cultivation or production wholesale operations.

On November 13, WeedMD announced that Health Canada approved its cannabis sales license for cannabis cultivated at its greenhouse in Ontario.

A look at Curaleaf Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. We’ll discuss analysts’ estimates for its EPS and revenue in this article. The chart above compares Curaleaf Holdings’ revenues since the third […]

Analysts expect 22nd Century Group to report revenue of $23.3 million in 2018, a 40.3% rise compared to $16.6 million in 2017.

Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.

Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.

Pfizer (PFE) released its third-quarter earnings on October 30.

As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”

Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.

Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.

Analysts are expecting GlaxoSmithKline’s revenues to increase 2.3% to 8.02 billion pounds for the third quarter of 2018.

Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.

Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.

Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.

Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.

Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

Analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to the third quarter of 2017.

Novartis’s (NVS) Sandoz is a market leader in differentiated generics.

For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”

Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.

Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.

Novartis released its third-quarter earnings results on October 18. Let’s see how it performed compared to analysts’ consensus estimates.

Pfizer is trading at a forward PE ratio of ~14.5x on October 18—compared to the industry average of ~15.7x.

Pfizer’s dividend yield is 3.15%. The company’s historical dividend yield was 3.53% in 2017, while the five-year average yield is 3.44%.

Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.

Pfizer’s total shares outstanding are ~5.862 billion. There are ~5.859 billion free-floating shares—nearly 99.95% of the total outstanding shares.

Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17.

Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018.

Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.

Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics.

Novartis’s Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue.

Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

Wall Street analysts estimate that INSY stock could decrease ~3% over the next 12 months. That show a 12-month target price of $9.60.

Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.

Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.

Five analysts are currently tracking GlaxoSmithKline ADR. One analyst recommends a “strong buy,” and four analysts recommend a “hold.”

Analysts expect Amgen’s (AMGN) stock price to fall ~1.4% over the next 12 months.

Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.

Nineteen analysts currently track Pfizer stock. The consensus rating for Pfizer stands at 2.63, which represents a “hold.”

Sixteen analysts currently track Eli Lilly (LLY) stock. Two analysts recommend a “strong buy,” six analysts recommend a “buy,” and eight analysts recommend a “hold.”

The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.

On October 2, Johnson & Johnson announced the completion of the divestiture of its LifeScan business to Platinum Equity for ~$2.1 billion.

Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.

Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.

GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018.

Analyst estimates suggest GlaxoSmithKline stock could rise ~6.3% over the next 12 months.

Eli Lilly’s Elanco reported a 1% YoY (year-over-year) rise in revenue to $792.1 million in the second quarter.

Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.

Eli Lilly and Company’s (LLY) market cap is ~$106.0 billion as of September 26.

Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.

Eli Lilly stock reported a ~0.6% rise to close at $106.31 on September 26 compared to the previous day’s close.

Eli Lilly and Company (LLY) stock has fallen a marginal ~0.1% so far in September, and its closing price was $105.59 on September 24.

Merck & Co. (MRK) stock has risen ~3.2% in the same period, with a closing price of $70.78 on September 24.

Pfizer’s dividend yield is 3.09%. Its dividend yield last year was 3.53%, and its five-year average yield is 3.44%.

The total number of Pfizer’s outstanding shares is ~5.862 billion. Of these, its free-floating shares total ~5.859 billion.

Pfizer reported a rise in revenue in international markets in the second quarter, though this growth was offset by lower sales in US markets.

Pfizer (PFE) reported EPS of $0.74 on revenue of ~$13.5 billion in the second quarter, surpassing Wall Street analysts’ consensus estimate.

Pfizer has divided its product portfolio into two segments: Innovative Health and Essential Health. It reports revenue for both these segments.

SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.

Allergan’s total investment in the Medical Aesthetics and Innovation Center is ~$14.7 million.

On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.

On September 21, 23 analysts tracked Allergan (AGN) stock. Four analysts recommended a “strong buy,” and 12 analysts recommended a “buy.”

Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.

Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.

Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.

Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.

Allergan (AGN) reported revenue of $4.1 billion in the second quarter, a 2.9% YoY (year-over-year) rise in revenue.

Merck & Co. (MRK) reported revenue of ~$10.5 billion in the second quarter, a 5% YoY (year-over-year) rise in revenue.

Pfizer (PFE) reported revenue of ~$13.5 billion in the second quarter, a 4% YoY (year-over-year) rise in revenue.

In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).